CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by IMA Wealth Inc.

IMA Wealth Inc. trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,681 shares of the company’s stock after selling 836 shares during the quarter. IMA Wealth Inc.’s holdings in CRISPR Therapeutics were worth $1,545,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the business. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after buying an additional 1,372,986 shares during the period. Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,538,725 shares of the company’s stock valued at $69,843,000 after buying an additional 7,635 shares during the period. Armistice Capital LLC lifted its holdings in shares of CRISPR Therapeutics by 20.0% in the 3rd quarter. Armistice Capital LLC now owns 600,012 shares of the company’s stock valued at $27,235,000 after buying an additional 100,012 shares during the period. Barclays PLC lifted its holdings in shares of CRISPR Therapeutics by 36.9% in the 3rd quarter. Barclays PLC now owns 510,832 shares of the company’s stock valued at $23,186,000 after buying an additional 137,629 shares during the period. Finally, Baillie Gifford & Co. lifted its holdings in shares of CRISPR Therapeutics by 81.1% in the 3rd quarter. Baillie Gifford & Co. now owns 441,063 shares of the company’s stock valued at $20,020,000 after buying an additional 197,469 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the sale, the chief executive officer now directly owns 208,122 shares of the company’s stock, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. Insiders sold a total of 133,992 shares of company stock valued at $9,157,835 over the last quarter. Company insiders own 4.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on CRSP shares. Barclays raised their price target on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a report on Thursday, February 22nd. Royal Bank of Canada lifted their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Citigroup lifted their price objective on CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, April 11th. Finally, Morgan Stanley lifted their price objective on CRISPR Therapeutics from $46.00 to $48.00 and gave the stock an “underweight” rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $76.29.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock traded up $0.18 during mid-day trading on Friday, hitting $53.91. 1,353,533 shares of the company were exchanged, compared to its average volume of 1,233,330. The business’s 50 day simple moving average is $70.57 and its two-hundred day simple moving average is $63.81. CRISPR Therapeutics AG has a 12-month low of $37.55 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The business had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. CRISPR Therapeutics’s revenue for the quarter was up 3253.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.41) EPS. On average, analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.